1.
Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications.J Crohns Colitis. 2019;13(2):144-164. doi:10.1093/ecco-jcc/jjy113
2.
Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):738-745. doi:10.1053/j.gastro.2009.12.037
3.
Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies.Clin Gastroenterol Hepatol. 2012;10(6):639-645. doi:10.1016/j.cgh.2012.01.010
4.
Bye WA, Ma C, Nguyen TM, Parker CE, Jairath V, East JE. Strategies for detecting colorectal cancer in patients with inflammatory bowel disease: a cochrane systematic review and meta-analysis.Am J Gastroenterol. 2018;113(12):1801-1809. doi:10.1038/s41395-018-0354-7
5.
Choi CR, Bakir IA, Hart AL, Graham TA. Clonal evolution of colorectal cancer in IBD.Nat Rev Gastroenterol Hepatol. 2017;14(4):218-229. doi: 10.1038/nrgastro.2017.1
6.
Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;14(25):3937-3947. doi:10.3748/wjg.14.3937
7.
Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?World J Gastroenterol. 2012;18(29):3839-3848. doi:10.3748/wjg.v18.i29.3839
8.
Cronin KA, Scott S, Firth AU, et al. Annual report to the nation on the status of cancer, part 1: National cancer statistics.Cancer. 2022;128(24): 4251-4284. doi:10.1002/cncr.34479
9.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023.CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763
10.
Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study.N Engl J Med. 1990;323(18): 1228-1233. doi:10.1056/NEJM199011013231802
11.
Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study.Lancet. 2020; 395(10218):123-131. doi:10.1016/S0140-6736(19)32545-0
12.
Amersi F, Agustin M, Ko CY. Colorectal cancer: epidemiology, risk factors, and health services.Clin Colon Rectal Surg. 2005;18(3):133-140. doi:10.1055/s-2005-916274
13.
Keller DS, Windsor A, Cohen R, Chand M. Colorectal cancer in inflammatory bowel disease: review of the evidence.Tech Coloproctol. 2019;23(1):3-13. doi:10.1007/s10151-019-1926-2
14.
Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors.Prz Gastroenterol. 2019; 14(2):89-103. doi:10.5114/pg.2018.81072
15.
Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases.Gastroenterology. 2004; 126(6):1634-1648. doi:10.1053/j.gastro.2004.03.025
16.
Rogler G. Chronic ulcerative colitis and colorectal cancer.Cancer Lett. 2014;345(2):235-241. doi:10.1016/j.canlet.2013.07.032
17.
O'Connor PM, Lapointe TK, Beck PL, Buret AG. Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease.Inflamm Bowel Dis. 2010;16(8):1411-1420. doi:10.1002/ibd.21217
18.
de Campos Silva EF, Baima JP, de Barros JR, et al. Risk factors for ulcerative colitis-associated colorectal cancer: a retrospective cohort study.Medicine (Baltimore). 2020;99(32):e21686. doi:10.1097/MD. 0000000000021686
19.
Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649-670. doi:10.1093/ecco-jcc/jjx008
20.
Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies.J Crohns Colitis. 2015;9(11):945-965. doi:10.1093/ecco-jcc/jjv141
21.
Han YD, Al Bandar MH, Dulskas A, et al. Prognosis of ulcerative colitis colorectal cancer vs. sporadic colorectal cancer: propensity score matching analysis.BMC Surg. 2017;17(1):28. doi:10.1186/s12893-017-0224-z
22.
Ananthakrishnan AN, Shi HY, Tang W, et al. Systematic review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease.J Crohns Colitis. 2016;10(10):1224-1236. doi:10.1093/ecco-jcc/jjw054
23.
Mañosa M, Calafat M, de Francisco R, et al. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study.Aliment Pharmacol Ther. 2018;47(5):605-614. doi:10.1111/apt.14494
24.
Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis.Gut. 2001;48(4):526-535. doi:10.1136/gut.48.4.526
25.
Kekilli M, Dagli U, Kalkan IH, et al. Low incidence of colorectal dysplasia and cancer among patients with ulcerative colitis: a Turkish referral centre study.Scand J Gastroenterol. 2010;45(4):434-439. doi:10. 3109/00365520903540830
26.
Ünal NG, Özütemiz Ö, Tekin F, Turan İ, Osmanoğlu N. Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey.Turk J Gastroenterol. 2019;30(2):139-147. doi: 10.5152/tjg.2018.18221
27.
Everhov ÅH, Erichsen R, Järås J, et al. Colorectal cancer in elderly-onset inflammatory bowel disease: a 1969-2017 Scandinavian register-based cohort study.Aliment Pharmacol Ther. 2022;56(7):1168-1182. doi:10. 1111/apt.17175
28.
Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study.Cancer. 2001;91(4):854-862. doi:10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z
29.
Tozun N, Atug O, Imeryuz N, et al. Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey.J Clin Gastroenterol. 2009;43(1):51-57. doi:10.1097/MCG. 0b013e3181574636